Skip to content

Evaluation of preservative-free Hydroxypropyl methylcellulose with Dextran for Dry eye symptoms in Diabetic patient after Phacoemulsification Surgery

Evaluation of preservative-free Hydroxypropyl methylcellulose with Dextran for Dry eye symptoms in Diabetic patient after Phacoemulsification Surgery

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20251003009
Enrollment
60
Registered
2025-10-03
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye condition in Diabetic mellitus type 2 patients undergoing cataract surgery (Phacoemulsification) Dry eye, Cataract surgery, Phacoemulsification, Diabetes

Interventions

Patients participating assigned to use antibiotic and steroid eye drops following surgery. Specifically, they will receive Moxifloxacin eye drops to be instilled four times daily, and Pred Forte eye
Standard treatment group,HPMC with Dextran group (Artificial tear group)

Sponsors

Faculty of Medicine, Thammasat University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes (previously diagnosed with a fasting blood glucose level more than 126 mg/dL), aged over 40 years, who have cataracts and undergo cataract surgery using the phacoemulsification technique. They must not present with symptoms of dry eye such as eye irritation, burning sensation, or photophobia and must have a Tear Break-Up Time (TBUT) of less than 10 seconds before surgery

Exclusion criteria

Exclusion criteria: 1. Patients whose cataracts are not related to aging or diabetes, such as cataracts resulting from trauma, uveitis 2. Patients undergoing cataract surgery in conjunction with other ocular procedures, such as retinal surgery.If intraoperative complications arise during cataract surgery that require a change in surgical technique from phacoemulsification to another method, data collection for that participant will be discontinued. 4. Patients with a known allergy to HPMC with Dextran. 5. Patients with systemic diseases associated with severe dry eye that require treatment with medications or artificial tears outside the scope of this study 6. Patients with corneal abnormalities or ocular diseases currently under treatment with medications that must be continued, as well as those who have undergone procedures related to dry eye

Design outcomes

Primary

MeasureTime frame
Dry eye 1 day, 1 week and 1 month Tear break up time, Tear meniscus height

Secondary

MeasureTime frame
Dry eye symptoms 1 day, 1 week and 1 month Ocular Surface Disease Index score

Countries

Thailand

Contacts

Public ContactThunyachanok Kasetrtut

Thammasat University Hospital

dream.thunchanokk@gmail.com0814693689

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026